Drug Type Antibody drug conjugate (ADC) |
Synonyms BCG012, DM 002(Xadcera Biopharma), DM002(Xadcera Biopharma) |
Target |
Action antagonists, inhibitors |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), MUC1 inhibitors(Mucin-1 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | - | 15 Jan 2025 | |
Colorectal Cancer | Phase 1 | - | 15 Jan 2025 | |
Endometrial Carcinoma | Phase 1 | - | 15 Jan 2025 | |
Ovarian Cancer | Phase 1 | - | 15 Jan 2025 | |
Prostatic Cancer | Phase 1 | - | 15 Jan 2025 | |
Breast Cancer | IND Approval | China | 12 Mar 2025 | |
Pancreatic Cancer | IND Approval | China | 12 Mar 2025 | |
Small Cell Lung Cancer | IND Approval | China | 12 Mar 2025 |